Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05206175 · ClinicalTrials.gov registry record · NA
Demonstration of a Digital Care Program for Methamphetamine Use Disorder
A NA study of Methamphetamine Abuse, sponsored by Affect Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05206175: Completed NA study of Methamphetamine Abuse, sponsored by Affect Therapeutics.
NCT05206175 is a NA study of Methamphetamine Abuse that has completed, run by Affect Therapeutics. The registered enrollment target is 100 participants, below the 202-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05206175, a NA study of Methamphetamine Abuse, has completed, sponsored by Affect Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase I Small Business Innovation Research (SBIR) project will examine the technical merit and real-world feasibility of the Affect smartphone application ("app") as the core component of the Affect digital care program for treatment of methamphetamine use disorder (MUD).
Primary Outcome
Participant retention and completion of the program will be measured as consistency of participant involvement through the end of the 8-week program, with criteria for completion being data on participation in \>50% of potential therapeutic interactions and activities. A related "time in treatment" measure will also characterize retention (and detail aspects of engagement). At the end-of-program telephone interview, participants will be deemed to be either treatment completers (i.e., retained) o
Conditions Studied
Interventions
- OTHER Affect Treatment Program for Methamphetamine Use Disorder
Study Locations (1)
New York
- Affect Therapeutics - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2022-12-31 |
| Phase | NA |
What the finished NCT05206175 record still lists
NCT05206175 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 202-participant average among 15 other Methamphetamine Abuse trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Methamphetamine Abuse appearing as the primary indexed condition, and to 1 intervention - of which Affect Treatment Program for Methamphetamine Use Disorder is the first listed.
NCT05206175 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05206175 about?
NCT05206175 is a clinical study titled "Demonstration of a Digital Care Program for Methamphetamine Use Disorder". This Phase I Small Business Innovation Research (SBIR) project will examine the technical merit and real-world feasibility of the Affect smartphone application ("app") as the core component of the Affect digital care program for treatment of methamphetamine use disorder (MUD).
What is the current status of trial NCT05206175?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2022-02-14. Estimated completion is 2022-12-31.
What conditions does trial NCT05206175 study?
This clinical trial studies the following conditions: Methamphetamine Abuse.
What interventions are being tested in trial NCT05206175?
The interventions under investigation include: Affect Treatment Program for Methamphetamine Use Disorder (OTHER).
Who is sponsoring clinical trial NCT05206175?
This trial is sponsored by Affect Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05206175 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05206175's enrollment target sits among peer trials
100 7th of 15 higher than 9 of 15 other Methamphetamine Abuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Methamphetamine Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
Theta Burst TMS for Treatment of Methamphetamine Use Disorder
RECRUITING · NA
-
rTMS for Craving in Methamphetamine Use Disorder
RECRUITING · NA
-
Mood and Decision-making in Methamphetamine Use Disorder
RECRUITING · NA
-
Contingency Management for Drug Use: Does Age Matter?
ACTIVE NOT RECRUITING · NA
-
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI